Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

155.64
+1.611.05%
Volume:176.77K
Turnover:27.42M
Market Cap:15.88B
PE:22.81
High:156.15
Open:154.31
Low:153.70
Close:154.03
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.51
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.30
PE(LYR):33.33

Loading ...

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

GlobeNewswire
·
Aug 10

Sector Update: Healthcare Stocks Rise Late Afternoon

MT Newswires Live
·
Aug 08

Neurocrine Launches Phase 1 Trial of NBIP-1968 Triple-Agonist Obesity Drug

Reuters
·
Aug 07

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Nbip-'1968, a Glp-1/Gip/Glucagon Receptor Triple Agonist

THOMSON REUTERS
·
Aug 07

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Aug 07

Nxera Pharma Swings to FY26 H1 Net Profit of JPY 1.59 Billion; Revenue Rises to JPY 18.91 Billion

Reuters
·
Aug 07

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 07

Voyager Q2 FY26 Net Loss Narrows to $24.47 Million; Revenue Falls to $3.17 Million

Reuters
·
Aug 07

Neurocrine is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 03

Neurocrine Amends 8-K to Update Pro Forma Financials for Soleno Acquisition

Reuters
·
Aug 01

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

TIPRANKS
·
Aug 01

Movement Alert|Neurocrine Biosciences Falls 9.92% in Regular Trading, Stock Under Pressure Despite Massive Q2 Earnings Beat

Market Focus
·
Aug 01

Neurocrine is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 31

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Sanofi (SNYNF)

TIPRANKS
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Regeneron (REGN) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 31

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $190 From $170, Maintains Hold Rating

MT Newswires Live
·
Jul 31

Neurocrine price target raised to $222 from $200 at Guggenheim

TIPRANKS
·
Jul 31

Neurocrine Biosciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Neurocrine Biosciences, Inc : Baird Raises Target Price to $225 from $186

THOMSON REUTERS
·
Jul 31

Neurocrine Director Leslie V. Norwalk Sells 1,250 Shares for $227,507.5

Reuters
·
Jul 31